"Since breast cancer is not a systemic disease from inception, when the imagers find *in situ* and 1-14 mm invasive breast cancer, it is the surgeon, specialized in the treatment of breast diseases, who should be the “quarterback” of the patient’s multidisciplinary team.”

Laszlo Tabar

**2012**

**BREAST SEMINAR SERIES**

LÁSZLÓ TABÁR, M.D., F.A.C.R. (Hon).

Course Director, Professor of Radiology

and an

INTERNATIONALLY RENOWNED FACULTY

**INTERDISCIPLINARY CONFERENCE**

on the diagnosis and treatment of early stage (*in situ* and 1-14 mm), nonpalpable breast cancer

**Florence/Firenze, Italy**

**Nov 27-29, 2012**

**Centro Congressi al Duomo, Firenze**

Designed for:

- Surgeons
- Pathologists / histotechnologists
- Radiologists / radiology technologists
- Gynecologists
- Medical and radiation oncologists
- Primary Care Physicians
- Nurses
- Administrators

interested in learning the current concepts of diagnosis and management of mammographically detected breast cancer

The emphasis in this course is on the team approach of diagnosing and treating mammographically detected, non-palpable breast cancers.

**18 HOURS OF CATEGORY I CME CREDITS**

For more information and registration please contact: Mammography Education, Inc.

Phone: (480) 419 0227  Fax: (480) 419 0219  e-mail: info@mammographyed.com
Interdisciplinary Conference: The team approach as a solution to the challenges in the modern health care era

PROBLEMS IN THE DIAGNOSIS AND TREATMENT OF MAMMOGRAPHICALLY DETECTED, EARLY, NONPALPABLE BREAST CANCERS

- In situ carcinoma and nonpalpable invasive breast cancers: diagnostic criteria and therapeutic challenges
- New therapeutic options in early stage breast cancer
- Axillary dissection: re-evaluation of its role in nonpalpable breast cancers
- Interventional diagnostic procedures: indications for larger bore needle biopsy and FNAB
- Emphasis upon effective teamwork

TARGET AUDIENCE

- Surgeons
- Radiologists
- Pathologists and Cytopathologists
- Medical and Radiation Oncologists
- Gynecologists / Primary Care Physicians
- Nurses
- Administrators

When the imagers find in situ and 1-14 mm invasive breast cancer, it is primarily a surgical disease” Laszlo Tabar

For registration and information, contact:

Ms. Donna Sokolik

Telephone: + 1 480 419 0227
Fax: + 1 480 419 0219
E-Mail: info@mammographyed.com

Registration online: www.mammographyed.com

CANCELLATION POLICY:

If it is necessary to cancel a registration, for any reason, please notify M.E.I. IN WRITING 30 DAYS PRIOR TO COURSE DATE to receive a 50% refund. To transfer from one course to another, a $75 administrative fee will be charged. We can only hold tuition for 1 year.
Faculty

Radiologist
László Tabár, M.D., F.A.C.R. (Hon).
Professor em. of Radiology
Uppsala School of Medicine
Department of Mammography
Falun, Sweden

Pathologist
Tibor Tot, M.D., Ph.D.
Associate Professor of Pathology
Uppsala School of Medicine
Chairman
Department of Clinical Pathology & Cytology
Falun Central Hospital
Falun, Sweden.

Radiation Oncologist:
Silvia C. Formenti, M.D.
New York University School of Medicine
The Sandra and Edward H. Meyer Professor of Radiation Oncology
Chair of the Department of Radiation Oncology
Professor of Medicine (Medical Oncology)
Associate Director, NYUCI
Leader, Breast Cancer Research Program
NYUCI, NYU Clinical Cancer Center, New York

Surgeon
Alberto Costa, M.D.
Executive Director of the Southern Switzerland Breast Unit, Lugano, Switzerland
Faculty

Radiologist

Alfonso Frigerio, M.D.
Regional Reference Center for Breast Cancer Screening, CPO-Piemonte, S. Giovanni Battista Hospital, Torino, Italy

Program Objectives:

Having participated in this course, the physician should:
• Understand the subgroups of in situ and invasive breast cancer.
• Have competence in the differential diagnosis of breast diseases and guide the diagnostic workup.
• Understand the importance of new therapeutic options in early stage breast cancer.
• Understand the role of local and systemic treatment in the management of image-detected nonpalpable breast cancer.
• To facilitate constructive teamwork among the members of the diagnostic and therapeutic team.
• Appreciate the importance of weekly tumor board meetings and cooperation among radiologists, surgeons and pathologists.
• Understand the value and relationship of the main prognostic factors in order to predict the outcome of the disease.
• Having attended this course, the participants are encouraged to develop comprehensive breast centers and organize regular pre-treatment planning conferences.

Professor of Surgery

Professor Luigi Cataliotti, M.D.
University of Florence, Italy
09:00  **INTRODUCTION** - *Professor L. Cataliotti* and *L. Tabár*

A. Breast cancer: A progressive, heterogeneous disease requiring interdisciplinary diagnosis and treatment - *L. Tabár*

B. 30-year experience with mammographic screening: What have we learned? - *L. Tabár*

10:00  Break

10:20  New Era pathology techniques: Large section histology - *T Tot*

11:00  Break


12:00  Lunch

1:15   Classification of *in situ* subtypes, based on imaging appearance. Part I. *In situ* carcinoma subtype presenting on the mammograms with *casting type* calcifications. The concept of neoductgenesis - *L Tabár, T Tot*

*Breaks at 2:30 & 3:45 PM*

**Panel discussion:** Treatment of this *special subtype* of *in situ* carcinoma. Faculty-faculty and faculty-audience interaction on the *in situ* carcinoma subtype presenting on the mammograms *with casting type* calcifications and other subtypes with neoductgenisis. *L. Tabár, A. Costa, T. Tot, A. Frigerio*

4:00   Cont. Treatment of this *special subtypes* of *in situ* carcinoma (Panel discussion) Faculty-faculty and faculty-audience interaction on the *in situ* carcinoma subtype presenting on the mammograms with *casting type* calcifications and other subtypes with neoductgenisis.

5:00   End of Day 1
2nd DAY

8:30 Heterogeneity of in situ carcinoma, cont. - L. Tabár, T. Tot
Classification of in situ carcinoma subtypes, based on imaging appearance: in situ carcinoma subtype presenting on the mammograms with crushed stone-like (pleomorphic) and powdery calcifications.

9:45 Break

10:00 Decision making regarding radiation therapy for "DCIS" - S. Formenti
Accelerated RT regimens in "DCIS" and in 1-14 mm invasive breast cancers - S. Formenti

10:45 Faculty-faculty and faculty-audience interaction. Panel discussion on the diagnosis and treatment of in situ carcinoma subtype presenting on the mammograms with crushed stone-like (pleomorphic) and powdery calcifications. L. Tabár, T. Tot, A. Costa, S. Formenti, A. Frigerio

11:15 Break

11:30 Cont.: Faculty-faculty and faculty-audience interaction. Panel discussion on the diagnosis and treatment of in situ carcinoma subtype presenting on the mammograms with crushed stone-like (pleomorphic) and powdery calcifications. A tumor board with the participation of: S. Formenti, L. Tabár, A. Costa, T. Tot, A. Frigerio

12:30 Lunch

1:45 NONPALPABLE INVASIVE BREAST CANCER

Breaks at 2:45 & 3:45 PM

A. How to find invasive breast cancer when it is 1-14 mm in size.
Mammographic prognostic features - L. Tabár

B. The problem of imaging "dense breasts" and a possible solution.
Essential pathology diagnosis of mammographically detected 1-14 mm invasive breast cancer. The issue of multifocality - T. Tot

4:00 Revolutionary ideas in art and science: from Renaissance Linear Perspective to the Foundation of Modern Science - A. Frigerio

5:00 End of Day 2

Mammography / large thin and large thick section histology images of Grade 2 in situ carcinoma localized in the TDLUs
New therapeutic possibilities in the treatment of primary invasive breast cancer - A. Costa

The need to re-examine axillary node dissection for early stage breast cancer - A. Costa

Correlation of mammographic/histologic appearance of impalpable 1-14 mm invasive breast cancer with 25-year old follow-up. The reliability of the “mammographic prognostic features” in predicting the long-term outcome of 1-14 mm invasive breast cancer cases. Suggestions for the reconsideration of current therapeutic practice and the TNM Classification System - L Tabár

Radiotherapy for patients with mammographically detected unifocal and multifocal 1-14 mm invasive breast cancers. Aggressive early breast cancers: basal tumors - S. Formenti

Comments: New research results based on mammographic prognostic features - L Tabár

Faculty-faculty and faculty-audience interaction on the diagnosis and treatment of mammographically detected, nonpalpable invasive "ductal" carcinoma using didactically grouped cases based on mammographic appearance. Diagnosis, differential diagnosis and treatment. A tumor board with the participation of: S. Formenti, A. Costa, T. Tot, L. Tabár, A. Frigerio

Faculty-faculty and faculty-audience interaction on the diagnosis and treatment of mammographically detected, nonpalpable invasive "ductal" carcinoma using didactically grouped cases based on mammographic appearance. Diagnosis, differential diagnosis and treatment.

Comparative effectiveness of RT courses: implications for global breast cancer - S. Formenti

Panel discussion on the diagnosis and treatment of mammographically detected, non-palpable stellate or circular tumor masses representing invasive ductal carcinoma subtypes, special forms - S. Formenti, L. Tabár, A. Costa, A. Frigerio

Histopathologic / mammographic correlation with long-term outcome in
* Invasive lobular carcinoma subtypes
* Tubular carcinoma  * Medullary carcinoma  * Colloid / mucinous carcinoma

End of Course
Mammography Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. Mammography Education, Inc. designed these medical education activities for a maximum of **18 credit hours in Category I** of the Physicians' Recognition Award of the American Medical Association.

Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This course also applies for the Italian System of CME credits (ECM). Italian physicians may claim only those hours of credit that she/he actually spent in the educational activity. The credits can be claimed through our Italian agent KONIKAB (see below)

**Italian Scientific Organizing Committee**

**Dott. Alfonso Frigerio, M.D.,** Ospedale S. Giovanni Battista, **Torino,** Italy

e-mail:.alfonso.frigerio@gmail.com

**CREDITS**

We would like to thank the sponsors for their support of the teaching seminars of Mammography Education, Inc (list of vendors will be presented at the beginning of the course)

**Information on hotel reservations and information for the Italian attendees**

**Konikab Congressi srl** - Bologna, Italy. Phone: (0039) - 051 - 385 328. Fax: (0039) 051-311 350.

**COURSE LANGUAGE**

**English** with simultaneous translation to **Italian.**
For more information and registration please contact:

Mammography Education, Inc.
4429 E. Spur Drive
CAVE CREEK, AZ 85331, USA

Phone: (480) 419 0227
Fax: (480) 419 0219
3-D histologic image of TDLUs

Computer simulation images of the development of Grade 2 *in situ* carcinoma within the TDLU. The lobule becomes gradually distended and deformed. Calcifications are formed within the necrotic debris and are seen on the mammogram as **crushed stone-like** calcifications.